Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 2000, p. 1992-1995, Vol. 38, No. 5
Division of Infectious Diseases, Department
of Medicine, University of Colorado Health Sciences Center, Denver,
Colorado
Received 13 October 1999/Returned for modification 14 January
2000/Accepted 21 February 2000
A real-time PCR assay for quantitation of Kaposi's
sarcoma-associated herpes virus (KSHV or human herpesvirus 8) DNA was
evaluated. The linear dynamic range was 10 to 105 copies of
KSHV DNA (r2 > 0.99). The accuracy of DNA
purification and quantitation was less than ±0.4 log10
copies for samples that contained from 10 to 105 copies of
KSHV DNA. Cell-associated KSHV DNA was quantitated over a range of
infected cell frequencies from 0.1 to 10 Detection of Kaposi's
sarcoma-associated herpesvirus (KSHV) DNA in peripheral blood
mononuclear cells (PBMC) from human immunodeficiency virus type
1-infected persons is associated with an increased risk of subsequent
development of Kaposi's sarcoma (13, 15) and with Kaposi's
sarcoma clinical stage (3, 10). However, previous studies of
the relationship between peripheral blood KSHV load and Kaposi's
sarcoma pathogenesis were limited by the use of qualitative or
semiquantitative estimates of KSHV load. Techniques that provide
accurate and reproducible measurements of the amount of KSHV in the
circulatory compartment are needed.
Real-time quantification of specific PCR products allows the accurate
determination of the amount of DNA template present at the start of the
reaction (for reviews, see references 6 and
7). During each PCR cycle, the amount of
fluorescence that occurs when a fluorogenic oligonucleotide probe is
activated by 5' to 3' exonuclease activity of Taq polymerase
after binding to a specific PCR product is monitored (Taqman PCR). The
number of PCR cycles required to reach a threshold fluorescence
(CT) is determined for each sample, and the
measured value of CT is compared to the values
of standards with known DNA template concentrations to determine the
starting template concentration in the sample. Because
CT is determined during the exponential phase of
PCR, the value of CT has a linear relationship
to the logarithm of the template DNA concentration. The purpose of the
present study was to evaluate the performance of a real-time PCR assay
to quantitate both cell-free and cell-associated KSHV DNA.
The real-time PCR assay used forward (5'-CTCGAATCCAACGGATTTGAC-3')
and reverse (5'-TGCTGCAGAATAGCGTGCC-3') primers
(Oligos Etc., Wilsonville, Oreg.) and the fluorogenic Taqman probe
(5'-CCATGGTCGTGCCGCAGCA-3'; PE Applied Biosystems, Foster
City, Calif.) to amplify and detect a 74-base pair amplicon in the KSHV
minor capsid protein gene (open reading frame 26, from nucleotides
47311 to 47384 of the KSHV genome). The nucleotide sequence targeted by
the primers and probe is highly conserved amongst isolates from the
three major subgroups of KSHV (2, 5, 14, 16). To prepare
KSHV DNA standards, a plasmid (pMCP) that contains nucleotides
47239 to 47554 of the KSHV genome was linearized with
HindIII and serially diluted into a salmon
sperm DNA carrier so that the total DNA concentration in all standards
was 0.2 µg/µl.
Human blood specimens were separated into plasma and PBMC by
centrifugation in Vacutainer cell preparation tubes containing 0.1 M
sodium citrate according to the manufacturer's instructions (Becton
Dickinson, Franklin Lakes, N.J.). BCP-1 cell growth conditions and the
BCP-1 cell immunofluorescent assay to detect antibodies to KSHV
latency-associated nuclear antigen were as previously described
(12). Prior to DNA extraction, PBMC or BCP-1 cells were
washed with phosphate-buffered saline and stored at Frozen cell pellets were thawed and resuspended in 200 µl of
phosphate-buffered saline, and DNA was extracted and purified with the
QIAamp Blood kit (Qiagen, Inc., Chatsworth, Calif.). Purified cell DNA
was quantitated by absorption spectroscopy at 260 nm and by real-time
PCR quantification of human Each PCR contained 2 µg of sample DNA (10 µl), 0.3 µM forward and
0.9 µM reverse primers, 0.2 µM fluorogenic Taqman probe, 0.3 mM
(each) dATP, dCTP, and dGTP, 0.6 mM dUTP, 50 mM KCl, 10 mM Tris-HCl (pH
8.3), 10 mM EDTA, 5.5 mM MgCl2, and 1.25 U of Taq polymerase in a final volume of 50 µl. PCR mixtures
were incubated at 95°C for 12 min and then cycled at 95°C for
15 s and 60°C for 1 min for a total of 50 cycles in an ABI PRISM
7700 Sequence Detection system. The KSHV DNA copy number per microgram
of PBMC DNA was converted to KSHV DNA copy numbers per 105
PBMC with 6.6 × 109 base pairs as an estimate of the
size of the diploid human genome. The value of
CT was determined by the first cycle number at
which fluorescence was greater than or equal to 10 times the
background. All PCR analyses were performed by a person who was blinded
to the identity of the samples.
In replicate independent experiments, the value of
CT had a linear relationship with the logarithm
of the amount of minor capsid DNA added to a PCR (Fig.
1). This relationship extended over a
10,000-fold range, from 10 to 105 copies of KSHV minor
capsid gene DNA. The values of CT obtained with
106 copies of KSHV minor capsid gene DNA differed
significantly from the linear relationship. Based on these findings,
all subsequent experiments used serial 10-fold dilutions of KSHV minor
capsid DNA (from 10 to 105 copies per reaction) as a
standard curve to determine the amount of KSHV DNA in samples. If the
estimated KSHV DNA copy number in a PCR was greater than
105, the sample DNA was diluted 10- to 1,000-fold into
salmon sperm carrier DNA, and PCR quantitation was repeated.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Quantitation of Cell-Free and Cell-Associated
Kaposi's Sarcoma-Associated Herpesvirus DNA by Real-Time PCR
![]()
ABSTRACT
Top
Abstract
Text
References
5, and cell-free
KSHV DNA in plasma was quantitated over a range of 100 to
106 copies/ml. Real-time PCR provides a convenient method
for quantitation of cell-free and cell-associated KSHV DNA in
laboratory and clinical specimens.
![]()
TEXT
Top
Abstract
Text
References
70°C as a dry
pellet of 3 × 106 cells.
-actin DNA with Taqman
-actin
reagents according to the manufacturer's instructions (PE Applied
Biosystems). Culture supernatants or plasma was centrifuged at
500 × g for 15 min to remove cell debris, and the DNA
present in 0.2 ml of clarified culture supernatant or plasma was
extracted and purified with the QIAamp Blood kit after the addition of
10 µg of salmon sperm DNA as a carrier. Prior to use in PCRs, the DNA
concentration of all samples was adjusted to 0.2 µg/µl. During all
DNA extractions and purifications, strict precautions were taken to
reduce the risk of false-positive results (9).

View larger version (13K):
[in a new window]
FIG. 1.
Relationship of threshold cycle to KSHV minor capsid DNA
copy number. The number of minor capsid DNA copies present in a PCR
reaction is indicated on the x axis, and the cycle number in
which fluorescence exceeded background is indicated on the y
axis (CT). For data obtained with 10 to
105 copies, the values of CT are the
mean of 12 replicates from seven independent experiments. The value of
CT at 106 copies is the mean of four
replicates from two independent experiments. Error bars indicate the
standard deviation for values of CT. The solid
line was obtained by linear regression analysis of the data from 10 to
105 copies (r2 > 0.99; P < 0.001), and dotted lines indicate the 95% confidence intervals
for the regression.
The accuracy of KSHV DNA purification and quantitation was determined
by extraction of DNA from replicate samples that contained from 10 to
105 copies of minor capsid DNA. The amount of KSHV DNA
present in the purified preparations was determined by real-time PCR
and compared to the amount that was expected if recovery was 100% (Fig. 2). The accuracy (i.e., the
difference between the true copy number value and the measured value)
of DNA purification and quantitation was ±0.37 log10 for
samples that contained 10 copies of minor capsid DNA and was less than
±0.2 log10 for samples that contained between 100 and
105 copies of minor capsid DNA. The 95% confidence
interval for the intersample variation (the sum of the variances from
the mean of replicate samples) was ±0.14 log10. Thus, the
method used for extraction and purification of DNA gave quantitative
recovery of template DNA over a 10,000-fold range of template DNA
concentrations.
|
The ability of the assay to detect and quantitate KSHV DNA in cultured
cells was assessed by the induction of KSHV lytic replication in
latently infected BCP-1 cells. Induction of viral lytic replication in
BCP-1 cells with 3 mM n-butyrate resulted in a 450-fold
increase in the amount of KSHV DNA in the culture supernatant within
48 h (Fig. 3). In contrast, the
amount of cell-associated DNA decreased slightly after the induction of
lytic replication, from an estimated 67 copies per latently infected
cell to 21 copies per cell at 48 h after induction of lytic
replication. Our estimate of 67 copies of KSHV DNA per latently
infected BCP-1 cell by real-time PCR is within our margin of error
(±0.4 log10 copies), similar to a previously reported
value of 150 KSHV genomes per BCP-1 cell (4).
|
The performance of real-time PCR for the quantitation of cell-free KSHV
DNA in human plasma was determined by serial dilution of the 72-h
culture supernatant from induced BCP-1 cells into plasma from a
KSHV-seronegative donor. Analysis of DNA purified from the duplicate
plasma samples found that cell-free KSHV DNA could be detected and
quantitated in human plasma at levels ranging from 100 to
106 copies/ml (Fig. 4A). The
95% confidence interval for the intersample variation among duplicate
plasma samples was ±0.09 log10 copies/ml. The 72-h culture
supernatant used in this experiment contained 7.8 log10
copies of KSHV DNA/ml (Fig. 3). After a 1:100 dilution of this culture
supernatant into human plasma, the measured amount of KSHV DNA was 5.9 log10 copies/ml. Since the measured value was, within
error, similar to the expected value of 5.8 log10 copies/ml, this finding provides evidence that quantitation of cell-free KSHV DNA was not affected by human plasma.
|
The performance of real-time PCR for quantitation of cell-associated
KSHV DNA was evaluated by serial dilution of latently infected BCP-1
cells into PBMC from a KSHV-seronegative donor. Each dilution was split
into duplicate samples that contained 3 × 106 cells,
and the DNA present in each duplicate was extracted and purified.
Real-time PCR analysis of purified DNA from the duplicate samples found
that KSHV-infected cells could be detected and quantitated over a range
of infected cell frequencies from 0.1 to 10
5 (from 5 to
5 × 104 copies/µg of PBMC DNA [Fig. 4B]). The
95% confidence interval for the intersample variation among duplicate
PBMC samples was ±0.24 log10 copies/mg.
Since clinical specimens are sometimes exposed to conditions that
affect subsequent DNA quantitation, we determined the effects of room
temperature incubation and multiple freeze-thaw cycles on KSHV DNA in
plasma and culture supernatant. Although the amount of KSHV DNA in
plasma was not affected by incubation at room temperature for 48 h
(
0.1 log10 copies/ml decrease from baseline), the amount of KSHV DNA present in BCP-1 culture supernatant decreased 0.5 log10 after 48 h at room temperature. The amount of
KSHV DNA in plasma or culture supernatant was not affected by five
freeze-thaw cycles (
0.1 log10 copies/ml decrease from baseline).
The specificity of real-time PCR quantitation of KSHV DNA was evaluated
by analysis of plasma and PBMC samples collected from eight KSHV- and
human immunodeficiency virus type 1-seronegative American female
laboratory workers. In all eight samples, the amount of human genomic
DNA present in the purified PBMC DNA specimens estimated by real-time
-actin DNA quantitation was similar to the expected level of 0.2 µg/µl (estimated by absorbance at 260 nm). Thus, in all cases the
purified PBMC DNA was of sufficient quality for use in quantitative
real-time PCR. Quantifiable levels of KSHV DNA were not detected in any
of eight plasma and PBMC specimens. For a single PBMC specimen,
fluorescence exceeded background in cycle 37 of PCR amplification, but
the value of CT corresponded to a KSHV DNA level
of 0.2 copies/2 µg of PBMC DNA (a value below the theoretical minimum
level of detection of 1 copy/2 µg). This finding suggests that
nonspecific amplification signals may occur in later PCR cycles, and
the specificity of the assay for detecting PBMC KSHV DNA at levels less
than 5 copies/µg is unknown.
In summary, we have described a real-time PCR assay for quantitation of both cell-free and cell-associated KSHV DNA in clinical and laboratory samples. The sensitivity and linear range of the real-time PCR assay is similar to those of previously described quantitative competitive PCR KSHV DNA assays (1, 8, 11). However, compared to quantitative competitive PCR, the real-time PCR assay is performed in a single closed tube and does not require post-PCR analysis of PCR product. Since the real-time PCR assay is performed in a 96-well format, it also provides convenient analysis of large numbers of samples. Our findings suggest that real-time PCR quantitation of KSHV DNA will be useful for future studies on peripheral blood KSHV load.
| |
ACKNOWLEDGMENTS |
|---|
PCR assays were performed by Uma Pugazhenthi in the Quantitative PCR Laboratory of the University of Colorado Cancer Center.
This work was supported by a grant from the National Cancer Institute (CA79398).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Campus Box B-168, UCHSC, 4200 East Ninth Ave., Denver, CO 80262. Phone: (303) 315-8311. Fax: (303) 315-8681. E-mail: thomas.campbell{at}uchsc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Boivin, G.,
A. Gaudreau,
E. Toma,
R. Lalonde,
J. P. Routy,
G. Murray,
J. Handfield, and M. G. Bergeron.
1999.
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.
Antimicrob. Agents Chemother.
43:377-380 |
| 2. | Caterino-de-Araujo, A. 1998. Human herpesvirus 8 group B and C variants circulating in Sao Paulo, Brazil. J. Infect. Dis. 177:1136-1137[Medline]. |
| 3. |
Cattani, P.,
M. Capuano,
I. Lesnoni La Parola,
R. Guido,
R. Santangelo,
F. Cerimele,
C. Masini,
G. Nanni,
G. Fadda, and D. Cerimele.
1998.
Human herpesvirus 8 in Italian HIV-seronegative patients with Kaposi sarcoma.
Arch. Dermatol.
134:695-699 |
| 4. | Drexler, H. G., C. C. Uphoff, G. Gaidano, and A. Carbone. 1998. Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia 12:1507-1517[CrossRef][Medline]. |
| 5. |
Foreman, K. E.,
S. Alkan,
A. E. Krueger,
J. R. Panella,
L. J. Swinnen, and B. J. Nickoloff.
1998.
Geographically distinct HHV-8 DNA sequences in Saudi Arabian iatrogenic Kaposi's sarcoma lesions.
Am. J. Pathol.
153:1001-1004 |
| 6. | Freeman, W. M., S. J. Walker, and K. E. Vrana. 1999. Quantitative RT-PCR: pitfalls and potential. BioTechniques 26:112-125[Medline]. |
| 7. |
Heid, C. A.,
J. Stevens,
K. J. Livak, and P. M. Williams.
1996.
Real time quantitative PCR.
Genome Res.
6:986-994 |
| 8. | Hoang, M. P., B. Barton Rogers, B. Dawson, and R. H. Scheuermann. 1999. Quantitation of 8 human herpesviruses in peripheral blood of human immunodeficiency virus-infected patients and healthy blood donors by polymerase chain reaction. Am. J. Clin. Pathol. 111:655-659[Medline]. |
| 9. | Kwok, S., and R. Higuchi. 1990. Avoiding false positives with PCR. Nature 339:237-238. |
| 10. |
Lebbe, C.,
F. Agbalika,
P. de Cremoux,
M. Deplanche,
M. Rybojad,
E. Masgrau,
P. Morel, and F. Calvo.
1997.
Detection of human herpesvirus 8 and human T-cell lymphotropic virus type 1 sequences in Kaposi sarcoma.
Arch. Dermatol.
133:25-30 |
| 11. | Lock, M. J., P. D. Griffiths, and V. C. Emery. 1997. Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8. J. Virol. Methods 64:19-26[CrossRef][Medline]. |
| 12. | Moore, P. S., S. Gao, G. Dominguez, E. Cesarman, O. Lungu, D. M. Knowles, R. Garber, P. E. Pellett, D. J. McGeoch, and Y. Chang. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70:549-558[Abstract]. |
| 13. | Moore, P. S., L. A. Kingsley, S. D. Holmberg, T. Spira, P. Gupta, D. R. Hoover, J. P. Parry, L. J. Conley, H. W. Jaffe, and Y. Chang. 1996. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 10:175-180[Medline]. |
| 14. |
Poole, L. J.,
J. Zong,
D. M. Ciufo,
D. J. Alcendor,
J. S. Cannon,
R. Ambinder,
J. M. Orenstein,
M. S. Reitz, and G. S. Hayward.
1999.
Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right-hand end.
J. Virol.
73:6646-6660 |
| 15. | Whitby, D., M. R. Howard, M. Tenant-Flowers, N. S. Brink, A. Copas, C. Boshoff, T. Hatzioannou, F. E. A. Suggett, D. M. Aldam, A. S. Denton, R. F. Miller, I. V. D. Weller, R. A. Weiss, R. S. Tedder, and T. F. Schulz. 1995. Detection of Kaposi's sarcoma associated herpes virus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346:799-802[CrossRef][Medline]. |
| 16. | Zong, J.-C., C. Metroka, M. S. Reitz, J. Nicholas, and G. S. Hayward. 1997. Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate. J. Virol. 71:2505-2511[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»